Testing CAR T cells put into the brain for high-grade glioma that came back or is getting worse
Original title: Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people, checking safety and the right dose.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial is testing a treatment made from a person's own immune cells, placed right into the brain.
Who this trial is for. This trial is for people with a high-grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary that has come back or is growing and getting worse. It tests the side effects and the best dose of CAR T cells given into the brain through a thin, flexible tube. CAR T cells are a person's own immune cells, changed in a lab so they will attack tumor cells.
Where it stands. There are no results to share. The trial is measuring side effects and looking for the best dose. The answer is not in yet. This trial has not reported results.
What this means, and what it doesn't
What it could mean: This is one of the ways new brain tumor treatments get tested. If your situation sounds like this, you can ask your care team about it. They can help you look at trials and talk through what makes sense for you.
What it doesn't mean: This does not mean the treatment works. A trial is a test, not a proven treatment. Joining one is not a guarantee that it will help you. It is not a promise of a cure.
Source: ClinicalTrials.gov, August 12, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.